Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri (PLUR) with a Buy rating and $12 price target The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its “differentiated” bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri’s bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLUR: